Unknown

Dataset Information

0

A population-based serological study of post-COVID syndrome prevalence and risk factors in children and adolescents.


ABSTRACT: Post-COVID syndrome remains poorly studied in children and adolescents. Here, we aimed to investigate the prevalence and risk factors of pediatric post-COVID in a population-based sample, stratifying by serological status. Children from the SEROCoV-KIDS cohort study (State of Geneva, Switzerland), aged 6 months to 17 years, were tested for anti-SARS-CoV-2 N antibodies (December 2021-February 2022) and parents filled in a questionnaire on persistent symptoms in their children (lasting over 12 weeks) compatible with post-COVID. Of 1034 children tested, 570 (55.1%) were seropositive. The sex- and age-adjusted prevalence of persistent symptoms among seropositive children was 9.1% (95%CI: 6.7;11.8) and 5.0% (95%CI: 3.0;7.1) among seronegatives, with an adjusted prevalence difference (ΔaPrev) of 4.1% (95%CI: 1.1;7.3). Stratifying per age group, only adolescents displayed a substantial risk of having post-COVID symptoms (ΔaPrev = 8.3%, 95%CI: 3.5;13.5). Identified risk factors for post-COVID syndrome were older age, having a lower socioeconomic status and suffering from chronic health conditions, especially asthma. Our findings show that a significant proportion of seropositive children, particularly adolescents, experienced persistent COVID symptoms. While there is a need for further investigations, growing evidence of pediatric post-COVID urges early screening and primary care management.

SUBMITTER: Dumont R 

PROVIDER: S-EPMC9708639 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications


Post-COVID syndrome remains poorly studied in children and adolescents. Here, we aimed to investigate the prevalence and risk factors of pediatric post-COVID in a population-based sample, stratifying by serological status. Children from the SEROCoV-KIDS cohort study (State of Geneva, Switzerland), aged 6 months to 17 years, were tested for anti-SARS-CoV-2 N antibodies (December 2021-February 2022) and parents filled in a questionnaire on persistent symptoms in their children (lasting over 12 wee  ...[more]

Similar Datasets

| S-EPMC4256207 | biostudies-literature
| S-EPMC7908375 | biostudies-literature
| S-EPMC11490480 | biostudies-literature
| S-EPMC11371695 | biostudies-literature
| S-EPMC10874377 | biostudies-literature
| S-EPMC8146298 | biostudies-literature
| S-EPMC10013140 | biostudies-literature
| S-EPMC5537448 | biostudies-other
| S-EPMC7838937 | biostudies-literature
| S-EPMC10206128 | biostudies-literature